Challenges of designing hepatic encephalopathy treatment trials

Hepatology

Volumn 38, Issue 2, 2003, Pages 527-529

  Sanaka, Madhusudhan R ^a   Ong, Janus P ^b   Mullen, Kevin D ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTITOL; LACTULOSE; NEOMYCIN; RIFAXIMIN;

AMMONIA BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROENCEPHALOGRAM; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0042766787     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0270-9139(03)80803-0     Document Type: Note

References (17)

1. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001;34:768-773.
2. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th world congresses of Gastroenterology, Vienna, 1998. HEPATOLOGY 2002;35:716-721.
3. Mullen KD, Dasarathy S. Hepatic encephalopathy. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver. 8th ed. Philadelphia: Lippincott-Raven, 1999;545-581.
4. Jones EA, Weissenborn K. Neurology and liver. J Neurol Neurosurg Psychiatry 1997;63:279-293.
5. Blei AT. Hepatic encephalopathy. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J, eds. Oxford Textbook of Clinical Hepatology. 2nd ed. Oxford, UK: Oxford Medical, 1998;765-783.
6. Bosch J, Bruix J, Mas A, Navasa M, Rodes J. Rolling review: the treatment of major complications of cirrhosis. Aliment Pharmacol Ther 1994;8:639-657.
7. Rosado B, Kamath PS. Transjugular intrahepatic portosystemic shunts: an update. Liver Transpl 2003;9:207-217.
8. Sanyal AJ, Freedman AM, Shiffman ML, Purdum PP 3rd, Luketic VA, Cheatham AK. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. HEPATOLOGY 1994;20:46-55.
9. Somberg KA, Reigler JL, LaBerge JM, Doherty-Simor MM, Bachetti P, Roberts JP, Lake JR. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am J Gastroenterol 1995;90:549-555.
10. Rossle M, Haag K, Noeldge G, Richter G, Wenz W, Farthmann E, Gerok W. Hemodynamic consequences of portal decompression: which is the optimal shunt? Z Gastroenterol 1990;28:630-634.
11. Schomerus H, Hamster W. Neuropsychological aspects of portal systemic encephalopathy. Metab Brain Dis 1998;13:361-377.
12. Lockwood AH. "What's in a name?" Improving the care of cirrhotics. J Hepatol 2000;32:859-861.
13. Gilberstadt SJ, Gilberstadt H, Zieve L, Buegel B, Collier RO, McClain CJ. Psychomotor performance defects in cirrhotic patients without overt encephalopathy. Arch Intern Med 1980;140:519-521.
14. Watanabe A, Sakai T, Sato S, Imai F, Ohto M, Arakawa Y, Toda G, et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. HEPATOLOGY 1997;26:1410-1414.
15. Mullen KD. Organizing a clinical trial with a new drug for hepatic encephalopathy: an experience with the FDA. In: Yurdaydin C, Bozkoya H, eds. Advances in Hepatic Encephalopathy and Metabolism in Liver Disease, ISHE 1999. Turkey: Ankara, 2000;427-430.
16. Conn HO, Leevy CM, Vhlaceviv ZR, Rodgers JB, Maddrey WB, Seef L, Levy LL. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1997;72:573-583.
17. Arroya V, Gines P, Gerses AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, et al. Definition and diagnostic criteria for refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. HEPATOLOGY 1996;23:164-176.